Synonyms: compound 264 [WO2015154039A2] | SY-1365 | SY1365
Compound class:
Synthetic organic
Comment: Mevociclib (SY-1365) is a cyclin-dependent kinase 7 (CDK7) inhibtor [1] that is claimed in Syros Pharmaceuticals' patent WO2015154039A2 [2]. It is being developed for potential to treat proliferative diseases. SY-1365 is a structural analogue of THZ1, and it covalently binds to the same cysteine residue located outside of the canonical kinase domain at which THZ1 binds.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
In a DiscoverX KINOMEscan screen 8 of 468 kinases including CDK7 were inhibited by >90% by 1 μM SY-1365. The 7 kinases other than CDK7 were RPS6KA6, DYRK1B, MAPK10, MAPK8, MAPK9, PIP4K2C and CDK15. However, in vitro inhibition may be less relevant in vivo for kinases that do not contain the appropriately positioned cysteine residue to which SY-1365 covalently binds. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|